The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities. A research team from ...
Various sayings equate going fast with going alone. But none of them apply to the gene expression journey described by a research team from the University of Göttingen. The team, led by Heike Krebber, ...
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...
Flamingo Therapeutics BV and Ionis Pharmaceuticals Inc.’s FTX-001 (also known as FLM-7523) is a potential first-in-class antisense oligonucleotide (ASO) targeting the human metastasis-associated lung ...
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...
DNA is the poster child for high-specificity binding. As long as their base sequences match, two complementary strands of DNA can navigate through a sea of biomolecules, find each other, and hold fast ...
Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback